Clinical trials: Breakthrough Cancer Pain
Breakthrough Cancer Pain
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain
Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. This is a phase I/IIa, pharmacokinetic, dose-response and safety study of inhaled fentanyl aerosol (25µg/dose) in Chinese patients with breakthrough…
- Trial name
- NCT04713189
- Testing
- Inhaled fentanyl aerosol
- Volunteers
- 96 people
- Sponsor
- Lee's Pharmaceutical Limited
Cancer
Efficacy and Safety of Intranasal Fentanyl in the Treatment of Breakthrough Pain (FT-018-IM)
Primary objectives: To confirm the efficacy of intranasal fentanyl titrated to doses 50, 100 or 200 µg for treatment of breakthrough pain (BTP) in cancer patients To establish long-term safety of treatment with intranasal…
- Trial name
- NCT00362583
- Testing
- Fentanyl
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Nycomed
Pain
Fentanyl for Breakthrough Pain in the Emergency Department
The goal of this clinical research study is to learn if fentanyl nasal spray can help decrease pain related to cancer when used with other drugs for pain.
- Trial name
- NCT01812759
- Testing
- Fentanyl Nasal Spray, Hydromorphone PCA
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer, Pain
Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability
Aim of this non-interventional study is to investigate the tolerability of Effentora® in cancer pain patients with breakthrough pain under real-life conditions in clinical practice.
- Trial name
- ERKENTNIS (NCT01400854)
- Testing
- Effentora®
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- Cephalon
Pain, Cancer
Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.
The purpose of this study is to determine the effectiveness and safety of sublingual fentanyl tablets in relieving breakthrough pain in cancer patients.
- Trial name
- NCT00262678
- Testing
- EN3267
- Where
- United States
- Sponsor
- Kyowa Kirin Co., Ltd.
Cancer, Pain
Sublingual Methadone for the Management of Cancer Breakthrough Pain
A dose titration protocol for sublingual methadone hydrochloride for the management of cancer-related breakthrough pain to find the optimal dose.
- Trial name
- NCT00125294
- Testing
- Methadone
- Volunteers
- 10 people
- Sponsor
- AHS Cancer Control Alberta
Breakthrough Pain
Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)
In cancer patients, pain is one of the most common symptoms. The range of reported prevalence of pain varies from 33% to 64% including different stages of cancer, during or after anticancer treatment.
- Trial name
- CAVIDIOM (NCT03435120)
- Testing
- No intervention
- Where
- 14 sites in Spain
- Volunteers
- 118 people
- Sponsor
- Angelini Farmacéutica
Pain
Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)
Primary: To compare the efficacy of nasal fentanyl (NF) to oral transmucosal fentanyl (Actiq®) (hereafter Actiq) in the management of breakthrough pain in cancer patients.
- Trial name
- NCT00496392
- Testing
- Nasal fentanyl
- Where
- Denmark
- Volunteers
- 115 people
- Sponsor
- Nycomed
Breakthrough Pain
Quality of Life Study Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent
In the context of radiotherapy, control of breakthrough pain represents a special challenge. Patients undergoing radiotherapy may experience different situations of pain that may be due to the need to remain immobilized during…
- Trial name
- CAVIDIOR (NCT02836379)
- Testing
- No intervention
- Where
- 11 sites in Spain
- Volunteers
- 79 people
- Sponsor
- Angelini Farmacéutica
Cancer, Pain
A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain
The purpose of this research study was to evaluate ARX-F02 (Sufentanil NanoTab) versus placebo ("sugar" pill or inactive substance) in the management of breakthrough pain in cancer patients.
- Trial name
- NCT00833040
- Where
- 13 sites in United States
- Volunteers
- 34 people
- Sponsor
- Talphera, Inc
Breakthrough Pain
Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients
A phase II, prospective, multicentre, single-blinded, randomised study (when fentanyl citrate is used outside of its marketing authorisation) Patients will be enrolled in an observational cohort when the fentanyl citrate is used…
- Trial name
- FARADI (NCT03809455)
- Testing
- Fentanyl citrate
- Sponsor
- UNICANCER
Pain, Cancer
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
The objective of the study is to monitor the safety (adverse event data) of longer-term use of ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) treatment in children with pain associated with cancer, sickle cell disease, or…
- Conditions
- Pain, Cancer, Sickle Cell Anemia, Severe Burns
- Trial name
- NCT00236093
- Testing
- ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])
- Where
- 28 sites in United States, Canada and 1 more
- Sponsor
- Cephalon
Advanced Cancers
Sublingual Fentanyl for the Management of Breakthrough Pain
The goal of this clinical research study is to learn if an investigational dose of fentanyl sublingual spray (FSS) can help to control pain in patients with advanced cancer when given in an outpatient and inpatient setting.
- Trial name
- NCT02514252
- Testing
- Fentanyl Sublingual Spray (FSS), Questionnaires, Mental Ability Tests
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Radiation-induced Oropharyngeal Mucositis, Swallowing-induced Breakthrough Pain
A Mucosal Contouring Method Based on Swallowing-induced Breakthrough Pain for Radiation-induced Oropharyngeal Mucositis
The performance of the predictive models for severe oropharyngeal mucositis established using current oral mucosal contouring method was unsatisfactory in nasopharyngeal carcinoma (NPC).
- Trial name
- NCT06287788
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Pain, Breakthrough
Efficacy of Injectable Fentanyl in Sublingual Route Versus Oral Morphine Syrup for Breakthrough Pain
Randomized control trial that to comparison the efficacy of injectable fentanyl in sublingual route versus oral morphine syrup for breakthrough pain in gynecologic cancer patients with chronic cancer pain Primary outcome : to…
- Trial name
- NCT05037539
- Testing
- Fentanyl Citrate 50Mcg/Ml Inj_#1, Morphine
- Where
- Thailand
- Volunteers
- 20 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Breakthrough Cancer Pain
A Dose Titration Study of Fentanyl Buccal Soluble Film for Breakthrough Cancer Pain in Taiwan
Primary Objective: To determine the feasible dose range of Painkyl® required for Taiwanese population. Secondary Objectives: To evaluate the efficacy of Painkyl® by calculating squared mean of pain intensity difference at 30…
- Trial name
- NCT03669263
- Testing
- Fentanyl buccal soluble film (FBSF)
- Where
- Taiwan
- Volunteers
- 36 people
- Sponsor
- Chang Gung Memorial Hospital
Pain, Cancer
Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients
The purpose of this study is to evaluate the long-term safety and effectiveness of EN3267 in treating breakthrough pain episodes in opioid cancer patients who are using stable doses of opioid medication.
- Trial name
- NCT00263575
- Testing
- EN3267
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Cancer Pain, Breakthrough Pain
Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients
Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. Fentanyl Buccal Tablet (FBT) is used for the treatment of BTP in adults with cancer who are already receiving maintenance opioid therapy for chronic…
- Trial name
- NCT00842829
- Testing
- Fentanyl Buccal Tablet (FBT)
- Where
- 123 sites in France, Germany and 5 more
- Volunteers
- 330 people
- Sponsor
- Cephalon
Pain, Cancer
Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients
To assess the safety and efficacy of PMI-150 (Intranasal Ketamine) as an analgesic for the treatment of breakthrough pain in cancer patients.
- Trial name
- NCT00492388
- Testing
- PMI-150 (intranasal ketamine)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Break Through Pain, Cancer
A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough Pain
The aim of this clinical trial was to demonstrate the efficacy of a 400 μg dose strength of intranasal fentanyl spray (INFS, Instanyl®) and to evaluate the safety and to establish long term tolerability of treatment with INFS…
- Trial name
- NOSE-400 (NCT01429051)
- Testing
- Intranasal Fentanyl Spray (INFS)
- Where
- 11 sites in Hungary, Norway and 1 more
- Volunteers
- 46 people
- Sponsor
- Takeda